-
2022-500535-36-00
5
Moderately to severely active ulcerative colitis
-
2022-500537-84-00
5
Moderately to severely active ulcerative colitis
-
2024-520209-38-00
5
2025-09-19
Obesity or Overweight
-
2024-516525-31-01
5
2025-07-14
Primary Biliary Cholangitis
-
2023-504265-23-00
4
2023-10-23
Crohn's disease
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-521319-38-00
4
2026-03-11
metastatic colorectal cancer
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2023-509551-14-00
5
2024-06-12
Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2024-518534-81-00
4
2021-07-01
metastatic colorectal cancer
-
2023-504741-32-00
4
2022-11-30
Moderately to Severely Active Crohn's Disease
-
2024-515156-21-00
5
2020-01-09
Ulcerative Colitis
-
2023-507705-34-00
5
2025-08-29
Moderate to Severe Active Ulcerative Colitis
-
2022-502393-16-00
5
2023-09-06
Moderately to Severely Active Ulcerative Colitis
-
2023-505458-16-00
5
2022-09-13
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio